Selected-GenAtlas references	SOURCE	GeneCards	NCBI Gene	Swiss-Prot	Orphanet	Ensembl
	HGNC	UniGene	Nucleotide	OMIM		UCSC

Home Page

FLASH GENE

Symbol

HDAC6

contributors: mct/npt/pgu - updated : 11-09-2018

HGNC name	histone deacetylase 6
HGNC id	14064

FLASH GENE DNA RNA EXPRESSION PROTEIN DISORDER ANIMAL & CELL MODELS

ASSOCIATED DISORDERS

corresponding disease(s)

CDRHX

Other morbid association(s)

Type Gene Modification Chromosome rearrangement Protein expression Protein Function constitutional     --low   in microtubule dynamics sufficient to decrease focal adhesion turnover, and decreased dynamics of hyperacetylated microtubules in HDAC6-inhibited cells compromises their capacity to mediate the focal adhesion dynamics required for rapid cell migration constitutional     --over   may, through its interaction with RUNX2, alter the IHH developmental pathway and thus lead to abnormal bone morphogenesis

Susceptibility

Variant & Polymorphism

Candidate gene	prime target for cancer chemotherapy
Marker
Therapy target
	System Type Disorder Pubmed neurology acquired   potential nontoxic therapeutic target for ameliorating CNS injury characterized by oxidative stress-induced neurodegeneration and insufficient axonal regeneration blood     therapeutic potential of HDAC6-specific inhibitors in endothelial barrier dysfunction neurology     HDAC6 inhibitors are a therapeutic strategy for hereditary axonopathies neuromuscular spinal muscular atrophy   with HDAC2 may be the most compelling targets for SMA therapy (inhibition of HDAC6 alters potentially the stability of the SMN protein by countering any mechanism that may promote the proteosome based degradation of SMN) neurology neurodegenerative   translational value of HDAC6 in ALS therapy is yet to be further evaluated cancer digestive   restoration of primary cilia in tumor cells by HDAC6 targeting may be a potential therapeutic approach for cholangiocarcinoma tumor kidney polycystic kidney , targeting HDAC6 to downregulate EGFR activity may provide a potential therapeutic approach to treat polycystic kidney disease neurology neurodegenerative alzheimer may be a therapeutic target for AD miscelleaneous urinary   targeting HDAC6 to downregulate EGFR activity may provide a potential therapeutic approach to treat polycystic kidney disease

ANIMAL & CELL MODELS

Hdac6 inhibitors reverse axonal loss in a mouse model of mutant Hspb1-induced Charcot-Marie-Tooth disease (